**Is trachoma an emerging public health problem in the Solomon Islands and Vanuatu?** **Conjunctival scarring, corneal pannus and Herbert’s pits in adolescent children**

Robert Butcher1\*, Junely Tagabasoe2, Joseph Manemaka3, Annie Bong4, Mackline Garae5, Lui Daniel4, Chrissy Roberts1, Becca L Handley1, Victor Hu1, Emma M. Harding-Esch1,6, Ana Bakhtiari7,8, Rebecca Willis7,8, Andreas Mueller9, John Kaldor10, Richard Le Mesurier11, David Mabey1, Anaseini Cama11, Oliver Sokana2, Fasihah Taleo5,12, Hugh R. Taylor13 & Anthony W. Solomon1,14\*.

**Author affiliations**

1. Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom
2. Eye Department, Solomon Islands Ministry of Health and Medical Services, Honiara, Solomon Islands
3. Health Promotion Department, Solomon Islands Ministry of Health and Medical Services, Honiara, Solomon Islands
4. Eye Department, Vanuatu Ministry of Health, Port Vila, Vanuatu
5. Department of Neglected Tropical Diseases, Vanuatu Ministry of Health, Port Vila, Vanuatu
6. Tropical Data, London, United Kingdom
7. Tropical Data, Decatur, USA
8. Task Force for Global Health, Decatur, GA, USA
9. Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
10. Kirby Institute, University of New South Wales, Sydney, Australia
11. The Fred Hollows Foundation, Carlton, Victoria, Australia
12. Country Office, World Health Organization, Port Vila, Vanuatu
13. Indigenous Eye Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
14. Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

**\*Corresponding and alternate corresponding authors**

Robert Butcher, [robert.butcher@lshtm.ac.uk](mailto:robert.butcher@lshtm.ac.uk)

Anthony Solomon, [solomona@who.int](mailto:solomona@who.int)

**Running title**

Is trachoma emerging in Melanesia?

**Key words**

Trachoma, conjunctival scarring, corneal pannus, Herbert’s pits

**Summary**

In Solomon Islands and Vanuatu communities in which active trachoma prevalence in children was previously high, prevalence of Herbert’s pits or pannus plus conjunctival scarring in 10–14-year-olds is low, suggesting risk of future trachomatous blindness here is also low.

**Abstract**

Background

In the Solomon Islands and Vanuatu, the sign trachomatous inflammation—follicular (TF) is common, but ocular infection with *Chlamydia trachomatis* is not. It is debatable whether azithromycin mass drug administration (MDA), the recommended antibiotic treatment strategy for trachoma’s elimination as a public health problem, is necessary in this setting. We set out to estimate what proportion of adolescents were at risk of future incidence or progression of trachomatous scarring.

Methods

A cross-sectional survey was undertaken of all children aged 10–14 years resident in communities identified as high-TF clusters during previous population-based mapping. Graders examined children for clinical evidence of trachomatous scarring, pannus and Herbert’s pits (HPs) or limbal follilcles in both eyes. A dried blood spot was collected from each child and tested for antibodies to *C.* *trachomatis*.

Results

A total of 492 children in 24 villages of the Solomon Islands and Vanuatu were examined. 35/492 (7%) of children had limbal signs (pannus and/or HPs) plus any conjunctival scarring. 9/492 (2%) had limbal signs and moderate or severe conjunctival scarring. 22% of children were anti-Pgp3 seropositve.

Conclusions

Few adolescents here are at risk of future complications from trachoma, implying that further antibiotic MDA is not currently required for trachoma elimination purposes in these settings.

**Introduction**

Trachoma is the most common infectious cause of blindness [1] and a neglected tropical disease targeted for global elimination as a public health problem. Trachoma is considered eliminated as a public health problem when three criteria are satisfied in each formerly-endemic district: (a) prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds <5%; (b) prevalence of trachomatous trichiasis (TT) unknown to the health system in ≥15-year-olds <0.2%; and (c) presence of a system to identify and manage incident cases of TT [2].

TT is caused by conjunctival scarring distorting the eyelid, which is a result of repeated ocular infection with *Chlamydia trachomatis* (*Ct*) and associated inflammation. In trachoma-endemic countries, most adults have some scarring, and ~1% of scarred individuals develop TT each year [3]. Alongside promoting facial cleanliness and improving access to water and sanitation, World Health Organization (WHO) guidelines recommend delivery of multiple annual rounds of azithromycin MDA where the TF prevalence in 1–9-year-olds ≥10% [4]. These interventions are undertaken to reduce *Ct* transmission intensity, in the hope that reduction in the number of lifetime episodes of infection and disease [5] will reduce the risk of today’s children developing conjunctival scarring in later life [6,7]. In most mapped areas of Melanesia, the TF prevalence in 1–9-year-olds exceeds 10% but the prevalence of TT is <0.2% [8–11]. Prevalence and transmission of ocular *Ct* are also very low [12,13]. As a consequence, the question of whether azithromycin MDA is needed in Melanesia has been discussed at length at regional and global levels [14,15].

One hypothesis for the discrepancy between TF and TT prevalence in Melanesia is that recent increases in population density [16] have driven an increase in TF prevalence. According to this hypothesis, the low TT prevalence indicates that recrudescence is so recent that those exposed to active (inflammatory) trachoma in childhood have not yet lived long enough to develop blinding sequelae. While empirical data to support this hypothesis are lacking [17], it is important to understand whether the current TF prevalence in 1­–9-year-olds is driving conjunctival scarring that might lead to future blindness. If it is, interventions against active trachoma are needed; if not, interventions are not indicated.

Upper pole corneal pannus and Herbert’s Pits (HPs) (referred to as “limbal signs” in this paper, since both are found at or adjacent to the sclerocorneal junction) are held to be specific, long-lived cicatricial markers of current or previous active trachoma [18–21]; importantly, in one cohort study [22], the presence of ≥2 mm of pannus conferred strong risk of development of severe conjunctival scarring over the course of >15 years follow-up. In another study, presence and severity of pannus was associated with visual impairment [23]. In light of previous evidence that most observed local TF was unassociated with current or previous ocular *Ct* infection, the prevalence of limbal signs in Melanesia was therefore predicted to be illuminating.

In designing the study, there were a number of additional considerations. First, existing data [12,13] on low prevalence ocular *Ct* infection and low *Ct* transmission intensity in children had failed to convinvce some stakeholders that MDA was not required. Second, there was no established cohort study in Melanesia from which scarring incidence could be estimated. Third, given the multiple competing priorities of public health systems and the general success of the trachoma elimination programme elsewhere [24], there was understandable enthusiasm to address the question quickly, enabling the respective programmes to move forward. Other potentially useful ways to estimate incidence of scarring or TT, such as a new cohort study, would take years to decades to generate useful data.

Thereforeprompted by the recommendations of a WHO expert consultation [14], we set out to investigate whether 10–14-year-olds already had conjunctival scarring and other, more specific limbal signs of previous active trachoma. A moderate-to-high prevalence of the combination of conjunctival scarring plus either of the limbal signs was felt at the WHO expert consultation to signify some risk of future trichiasis that would be unequivocally trachoma-related.

Our aim was to determine the prevalence of pannus, HPs and conjunctival scarring in children living in villages in which a high proportion of 1–9-year-olds previously had TF. Few contemporary estimates of population prevalence of limbal disease have been made [22,25,26], therefore for the purposes of this study, data from Australia [23] were used to set an *a priori* threshold for continuation/cessation of MDA. As ocular *Ct* infection is a key risk factor for incidence and progression of conjunctival scarring, the study also collected capillary blood specimens for assessment of anti-*Ct* antibodies.

**Methods**

Study ethics, consent and data management

Protocols were approved by the London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee (15262), the Solomon Islands National Health Research Ethics Committee (12/06/18), the Vanuatu Ministry of Health Ethics Board (DPH 06/17/2-LT/mg) and the Ethics Review Committee of the WHO Regional Office for the Western Pacific (2018.4.VAN.1.CSU).

Village heads provided verbal consent to enrol villages, and household heads provided verbal consent to enrol households. Each participant’s parent or guardian provided written consent, and participants themselves provided verbal assent. Participants with trachoma were offered treatment in accordance with national guidelines.

Data were collected using smartphone-based electronic data collection forms, encrypted and uploaded to secure cloud storage, hosted by Tropical Data (www.tropicaldata.org).

Study population

We sought villages where high proportions of 1–9-year-olds had previously had TF [27,28]. Thresholds for inclusion were set arbitrarily at 20% and 30% TF in Vanuatu and Solomon Islands, respectively [14]. In pre-MDA trachoma surveys in Melanesia, each cluster was an individual village [27,28]. Villages for inclusion here were therefore identified by extracting age- and gender-adjusted cluster-level TF prevalences from the pre-MDA programmatic survey data [27,28]. Figure 1 shows histograms of cluster-level pre-MDA TF prevalence in Vanuatu and Solomon Islands, and indicates the fractions selected for inclusion.

In Vanuatu, the pre-MDA survey cluster-level TF prevalence in 1–9-year-olds was ≥20% in 11 villages in June–July 2016 [28]. Of these villages, two were excluded due to activity of the Manaro Voui volcano on nearby Ambae and resultant evacuation [29]. The mean cluster-level TF prevalence in 1–9-year-olds during pre-MDA mapping in the remaining nine selected villages was 29% (range: 20–51%).

In Temotu and Western provinces, Solomon Islands, the pre-MDA survey cluster-level TF prevalence in 1–9-year-olds was ≥30% in 16 villages in September–November 2013 [27]. One of these villages was excluded because it would have taken a disproportionately long time to re-visit. The mean cluster-level TF prevalence in 1–9-year-olds during pre-MDA mapping in the remaining 15 selected Solomon Islands villages was 46% (range: 30–64%).

Children aged 10–14 years living in each selected village were recruited because, in the hypothesised scenario of re-emergence, these individuals would have had time to develop scarring since the pre-MDA surveys. Teams went house-to-house to register all 10­–14-year-olds (both present and absent). They also recorded total numbers of household residents. Where a child was temporarily absent, teams made a return visit to the household or, where possible, visited the child’s school.

Examination

Elements from three established trachoma grading systems were employed (Table 1). Presence and severity of tarsal conjunctival scarring were assessed using the 1981 modified WHO grading scheme [30]. For assessment of pannus and HPs, a modified subset of the “minimal examination” criteria from the 1966 WHO trachoma grading scheme [31] was used. For simplicity, active and inactive pannus were not differentiated, inflammatory corneal infiltration was not graded, and current limbal follicles were graded as HPs.

Field examinations were carried out by ophthalmic nurses (field graders). Two months before the survey, the field graders undertook a two-day training programme on the grading of conjunctival scars, pannus and HPs; they then participated in a one-day refresher course immediately before the survey started. These training sessions involved presentation of photographs of typical cases, discussion of key features and an assessment of photographs. For the first week of fieldwork, all field graders were supervised in the field by experienced trachoma graders.

Photography

The objective for collecting photographs was to determine their utility for future studies by comparing agreement with field grades. High-resolution digital photographs were taken of the conjunctiva and upper pole of the limbus of each eye. Low quality and obscured photographs were discarded prior to random selection for grading. A random sample of 60 conjunctival and 60 limbus photographs was graded by two independent ophthalmologists with substantial experience of trachoma grading. Two analyses were conducted. First, field grades on scarring, pannus and HPs were compared to photograph grades independently assigned by photograder (PG) 1 and PG2 using weighted kappa scores. Second, the two PGs met to discuss photographs for which a photograph grade discrepancy had occurred. For this discussion, PGs were provided with their own independent grades and the field grades and asked to come to a consensus as to whether there was any scarring (C≥1) in a conjunctival photograph or any limbal disease (pannus ≥2 mm or ≥1 HP) in a limbal photograph. This consensus grade was then compared to the field grade. Where either PG felt a grade could not be assigned due to lack of image clarity, they were omitted from the comparison.

Serological testing

Blood was collected, dried and stored as described previously [13]. Dried blood spots (DBS) were shipped to LSHTM and tested for anti-Pgp3 antibodies using the Luminex system. The assay used was modified from [32] by utilising a secondary antibody with prebound streptavidin rather than adding secondary antibody and streptavidin in separate steps. A serial dilution of high-titre serum, low-titre serum and buffer without serum were run in triplicate as controls on each plate. The threshold net median fluorescence intensity (MFI) for seropositivity was determined as 815 by receiver–operator curve analysis against a panel of previously-characterised positive (n=34) and negative (n=35) samples [32].

Data analyses

Primary outcome measures were the prevalence of defined combinations of signs in 10–14-year-olds, as pre-specified by the WHO expert consultation: (i) limbal signs (pannus, HPs or both) in at least one eye plus conjunctival scarring (C1, C2 or C3) in at least one eye; and (ii) limbal signs in at least one eye and moderate-to-severe conjunctival scarring (C2 or C3) in at least one eye. Because a grader in the field can examine the eye in three dimensions for as long as needed, participant-willing, these outcome measures were based on the field grade.

The relationship between any limbal sign with age, gender, TF, country of residence, anti-Pgp3 serostatus and presence of scarring was tested using mixed-effects logistic regression (lme4::glmer function in R). Village of residence was included as a random effect in all models to account for clustering of trachoma at village level. For each independent fixed-effect variable to be included in the multivariable mixed-effects model, it had to be (a) associated with limbal signs in univariate analysis (*p*<0.1) and (b) not strongly correlated with another independent variable (polycor::hetcor function in R). Significance of association was tested with likelihood ratios.

**Results**

Study population

We visited 24 villages. We recruited and examined 492 residents aged 10–14 years, constituting 93% of individuals in that age group living in selected villages during the study (Table 2). Of 41 non-responders, 34 (83%) were absent on the day of examination, two (5%) refused and specific reasons for non-participation were not recorded for five.

Clinical examination

Examination results are in Table 3. A larger proportion of 10–14-year-olds in the Solomon Islands had TF than in Vanuatu (83/323 [26%] versus 8/169 [5%]; Welch t-test *p*<0.001). The proportion of participants with a scarring grade of C≥1 in at least one eye was higher in the Solomon Islands than in Vanuatu (112/323 [35%] versus 18/169 [11%]; Welch t-test *p*<0.001). Of those with scarring in at least one eye, 54/130 (42%) had scarring in one eye but not the other. A further 12/130 (9%) individuals with scarring had two scarred eyelids which differed in scarring severity. Scarring was not associated with gender or age, but was less common in participants with TF (ordered logistic regression *p*=0.02).

In total, 87/492 (18%) children had limbal signs in at least one eye (Table 3). 47/61 (77%) cases of pannus and 24/51 (47%) cases of HPs were bilateral. Limbal signs were more common in people with TF (adjusted odds ratio [aOR]: 4.30, 95% confidence interval [CI]: 2.25–8.22, *p*<0.001; Supplementary Table 1) and also more common in those with conjunctival scarring (aOR: 2.30, 95% CI: 1.28–4.14, *p*=0.006; Supplementary Table 1). Limbal signs were less common in females (aOR: 0.48, 95% CI: 0.28–0.82, *p*=0.007; Supplementary Table 1). Neither serostatus nor age were independently associated with limbal signs (Supplementary Table 1).

Scars and limbal signs

35/492 (7%) children had both a limbal sign and any conjunctival scarring (C≥1). 9/492 (2%) had both a limbal sign and moderate-to-severe conjunctival scarring (C≥2) (Table 4). Cases of moderate-to-severe scars and limbal signs were not evenly distributed within either country. The proportions of children affected in each visited village in the Solomon Islands and Vanautu are shown in Figure 2.

Photograph grading

The inter-grader agreement between PG1, PG2, PG concensus and field grade is shown in Table 5. In general, PGs called more cases of limbal features and fewer cases of conjunctival scarring than field graders.

Anti-Pgp3 serology

The age-specific anti-Pgp3 seroprevalence is showin in Figure 3. In the Solomon Islands, 30% (96/323) of participants had antibody levels in excess of the seropositivity threshold. In Vanuatu, 7% (11/169) had antibody levels in excess of the threshold. There was not strong evidence of a increase in seropositivity with age in either country (logistic regression: *p=*0.117 and *p*=0.053).

**Discussion**

Trachoma makes only a very small contribution to the overall burden of blindness and visual impairment in the Western Pacific Region [33], and it is therefore apposite to consider whether WHO-recommended interventions for eliminating trachoma as a public health problem are locally relevant. We found the prevalence of pannus and/or HPs plus conjunctival scarring in 10–14-year-olds in Vanuatu and the Solomon Islands to be <20%, below a pre-defined threshold for continuation of antibiotic MDA for trachoma [14].

Based on data on limbal signs in trachoma-endemic communities in Guinea Bissau and Taiwan, if TF in the Solomon Islands and Vanuatu was genuinely trachomatous, we could expect 60–80% of those with TF and 20–40% of those without active trachoma to have pannus and/or HPs [21,25]; the prevalence in these villages is demonstrably lower than that. In one previous study [22], ~90% of individuals with pannus had some degree of conjunctival scarring; in our study, 27% of those with limbal signs had concurrent scarring, suggesting that what we are observing in the Solomon Islands and Vanuatu is unlikely to be blinding trachoma. Previous data from Melanesia have shown a low prevalence of ocular *Ct* infection, a low intensity of *Ct* transmission among children, a relatively low prevalence of scars and rare-to-absent TT in adults [11,12,27,28]. Together with the current data on limbal disease, it could be concluded that the priority for addressing trachoma in these islands would be to focus on attempting to maintain low *Ct* transmission through facial cleaniliness and improving hygiene facilities rather than reducing *Ct* prevalence through antibiotic distribution.

This survey was intended to generate data to address a specific question to guide policy-making in the Pacific [14]. The study design had several limitations. First, the identification of villages for inclusion was opportunistic and based on available data from cluster-sampled surveys rather than a complete list of villages in each evaluation unit. Other hot-spots of disease could exist outside the villages included here. Second, it is clear from the comparison of field to photograph grades that grading of scarring, pannus and HPs can be inconsistent; similar questions have previously been identified in the use of photographs for diagnosing signs of active trachoma [34,35]. Third, we did not directly test for ocular *Ct* infection in this study. This was because extensive infection testing had already been done in Solomon Islands and Vanuatu and the prevalence of infection was known to be low in young children (~1% of 1–9 year olds in the most recent surveys in Temotu and Vanuatu [12,28]), who are at highest risk of infection [36]. In addition, as trachomatous scarring often develops and worsens in older people in the absence of ongoing *Ct* infection [37,38], presence or absence of infection in our study subjects was not felt to be predictive of future cicatricial disease. Fourth, antibodies to Pgp3 cannot distinguish between exposure to ocular or urogenital strains; the possibility that some of our seropositive children had seroconverted due to exposure to non-ocular strains cannot be ruled out. In fact, due to exposure to *Ct* in mothers’ urogenital tracts at parturition [39,40], ~10% of 1-year-olds in the Solomon Islands [13] and ~5% of 1-year-olds in Vanuatu [28] are seropositive. Our observed seroprevalence is therefore unlikely to be exclusively attributable to ocular exposure. This supports the hypothesis that transmission of ocular *Ct* is low in these communities. Finally, there are limited comparator data on pannus and HPs and their distribution in trachoma-endemic settings. While these two signs are said to be pathognomonic (or at least highly specific) for trachoma [22], empirical data to demonstrate their specificity are lacking.

In light of these methodological limitations and the specialized nature of the expertise required for its application, we do not recommend surveys of scarring and limbal signs for routine application in assessing need for interventions against active trachoma. Further research should be conducted on pannus and HPs to better characterise the significance of these signs. In the meantime, however, these data suggest that antibiotic MDA is not needed for trachoma elimination purposes in the Solomon Islands or Vanuatu.

**Conflict of interest**

None of the authors declare any conflict of interest.

**Funding**

Fieldwork was funded by The Fred Hollows Foundation. Laboratory work and the salaries of RB and BLH were funded by the Fred Hollows Foundation, the Queen Elizabeth Diamond Jubilee Trust and the International Trachoma Initiative through a collaborative award managed by The Fred Hollows Foundation [1954-0].

EHE is funded by the International Trachoma Initiative (ITI). ITI is a program of The Task Force for Global Health, and receives funding from Pfizer Inc. Neither ITI nor Pfizer Inc. had any role in the study’s design; in the collection, analysis and interpretation of data; in the writing of the publication; or in the decision to submit for publication.

**Acknowledgements**

We thank the residents of the Solomon Islands and Vanuatu who took part in the study; the field teams in Vanuatu (Bruce Obed, Kalo Berry, Prudence Rymil) and the Solomon Islands (Chillion Evans, Eric Suri, Annie Rofeta and Nigel Telikimaoli) who helped collect the data; and Diana Martin and Sarah Gwyn (US Centres for Disease Control and Prevention) who provided reagents for the anti-Pgp3 Luminex assay.

FT and AWS are staff members of the World Health Organization. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

**Author contributions:**

Study conception and design: RB, AM, JK, RLM, DM, AC, HRT, AWS

Study planning and implementation: RB, CR, BLH, EHE, ABa, RW, AM, RLM, AC, OS, FT, AWS

Training: RB, JT, JM, BLH, RLM, AC, HRT, AWS

Data collection: RB, JT, JM, ABo, GM, LD, BLH, VH, AC, OS, FT

Data curation and analysis: RB, EHE, RW, ABa

Report preparation: RB

Report revision and approval: RB, JT, JM, AB, GM, LD, CR, BLH, VH, EHE, ABa, RW, AM, JK, RLM, DM, AC, OS, FT, HRT, AWS

**References**

1. Bourne RA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Heal **2013**; 1:e339-49.

2. World Health Organization. Validation of elimination of trachoma as a public health problem (WHO/HTM/NTD/2016.8). Geneva, Switzerland: 2016.

3. Ramadhani AM, Derrick T, Holland MJ, Burton MJ. Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease. PLoS Negl Trop Dis **2016**; 10:e0004859.

4. Francis V, Turner V. Acheiving community support for trachoma control: a guide for district health work (WHO/PBL/93.36). Geneva, Switzerland: World Health Organization: 1995.

5. Gambhir M, Basáñez M-G, Burton MJ, et al. The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Negl Trop Dis **2009**; 3:e462.

6. West SK, Muñoz B, Mkocha H, Hsieh YH, Lynch MC. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol **2001**; 8:137–44.

7. Ramadhani AM, Derrick T, MacLeod D, et al. Progression of scarring trachoma in Tanzanian children: A four-year cohort study. PLoS Negl Trop Dis **2019**; 13:1–16.

8. Ko R, Macleod C, Pahau D, et al. Population-Based Trachoma Mapping in Six Evaluation Units of Papua New Guinea. Ophthalmic Epidemiol **2016**; 23:22–31.

9. Sokana O, Macleod CK, Jack K, et al. Mapping trachoma in The Solomon Islands – results from the Global Trachoma Mapping Project. Ophthalmic Epidemiol **2016**; 23:15–21.

10. Macleod CK, Butcher R, Mudaliar UU, et al. Low prevalence of ocular Chlamydia trachomatis infection and active trachoma in the Western Division of Fiji. PLoS Negl Trop Dis **2016**; 10:e0004798.

11. Taleo F, Macleod CK, Marks M, et al. Integrated mapping of yaws and trachoma in the five northern-most provinces of Vanuatu. PLoS Negl Trop Dis **2017**; 11:e0005267.

12. Butcher RMR, Sokana O, Jack K, et al. Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naïve Trachoma-Endemic Region of the Solomon Islands. PLoS Negl Trop Dis **2016**; 10:e0004863.

13. Butcher R, Sokana O, Jack K, et al. Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis. Wellcome Open Res **2018**; 3.

14. WPRO WHO. Expert Consultation on trachoma in the Pacific Islands (RS/2018/GE/02[AUS]). Melbourne, Australia: 2018.

15. World Health Organization. Report of the 4th Global Scientific Meeting on Trachoma, Geneva, 27–29 November 2018 (WHO/CDS/NTD/PCT/2019.03). Geneva: Switzerland: 2019.

16. Firth S. Instability in the Pacific Islands: a status report. Sydney, Australia: 2018.

17. Handley R, Roberts C h, Butcher R. A systematic review of historical and contemporary evidence of trachoma in the Pacific Islands. PLoS One **2018**; 13:e0207393.

18. Duke-Elder W. Textbook of ophthalmology. Volume II: Clinical methods of examination, congenital and developmental anomalies, general pathological and therapeutic considerations, diseases of the outer eye. London: Henry Kimpton, 1937.

19. Assaad FA, Maxwell-Lyons F. The use of catalytic models as tools for elucidating the clinical and epidemiological features of trachoma. Bull World Health Organ **1966**; 34:341–355.

20. Woodhouse D. Some problems of trachoma diagnosis. Trans Ophthalmol Soc UK **1973**; 93:635–40.

21. Derrick T, Holland MJ, Cassama E, et al. Can corneal pannus with trachomatous inflammation - follicular be used in combination as an improved specific clinical sign for current ocular Chlamydia trachomatis infection? Parasit Vectors **2016**; 9.

22. Dawson CR, Juster R, Marx R, Daghfous MT, Djerad A Ben. Limbal disease in trachoma and other ocular chlamydial infections: Risk factors for corneal vascularisation. Eye **1989**; 3:204–209.

23. Royal Australian College of Ophthalmologists. The national trachoma and eye health program of the Royal Australian College of Ophthalmologists. Sydney, Australia: 1980.

24. Solomon A, Emerson P, Resnikoff S. Trachoma then and now: update on mapping and control. Community Eye Heal **2017**; 30:90–91.

25. Kimura K, Obayashi T, Iwaki S, Kitamura M. Studies on the trachomatous pannus. 1. Clinical appearance and frequency of trachomatous pannus. Rev Int du Trach **1958**; 35:295–304.

26. Radnot M, Pajor B. [The incidence of trachomatous pannus.]. Rev Int du Trach **1961**; 38:311–313.

27. Sokana O, Macleod CK, Jack K, et al. Mapping Trachoma in the Solomon Islands: Results of Three Baseline Population-Based Prevalence Surveys Conducted with the Global Trachoma Mapping Project. Ophthalmic Epidemiol **2016**; 23:15–21.

28. Butcher R, Handley B, Taoaba R, et al. Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma. J Infect **2020**; 80:454–461.

29. McGarry D. Ambae is in crisis. Vanuatu Dly. Post. 2018;

30. Dawson CR, Jones BR, Tarizzo ML, World Health Organization. Guide to trachoma control in programmes for the prevention of blindness. Geneva, Switzerland: World Health Organization: 1981.

31. World Health Organization. Fourth WHO scientific group on trachoma research. Geneva, Switzerland: 1966.

32. Goodhew EB, Priest JW, Moss DM, et al. CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis **2012**; 6:e1873.

33. Keeffe JE, Casson RJ, Pesudovs K, et al. Prevalence and causes of vision loss in South-east Asia and Oceania in 2015: Magnitude, temporal trends and projections. Br J Ophthalmol **2019**; 103:878–884.

34. Solomon AW, Bowman RJC, Yorston D, et al. Operational evaluation of the use of photographs for grading active trachoma. Am J Trop Med Hyg **2006**; 74:505–508.

35. Gebresillasie S, Tadesse Z, Shiferaw A, et al. Inter-Rater Agreement between Trachoma Graders: Comparison of Grades Given in Field Conditions versus Grades from Photographic Review. Ophthalmic Epidemiol **2015**; 22:162–9.

36. Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet **2003**; 362:198–204.

37. Hu VH, Massae P, Weiss HA, et al. Bacterial infection in scarring trachoma. Invest Ophthalmol Vis Sci **2011**; 52:2181–6.

38. Burton MJ, Rajak SN, Hu VH, et al. Pathogenesis of progressive scarring trachoma in ethiopia and Tanzania and its implications for disease control: two cohort studies. PLoS Negl Trop Dis **2015**; 9:e0003763.

39. Schachter J, Holt J, Goodner E, Grossman M, Sweet R, Mills J. Prospective study of chlamydial infection in neonates. Lancet **1979**; 2:377–380.

40. Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. J Am Med Assoc **1986**; 255:3374–3377.

41. Marks M, Kako H, Butcher R, et al. Prevalence of sexually transmitted infections in female clinic attendees in Honiara, Solomon Islands. BMJ Open **2015**; 5.

42. Sullivan E, Abel M, Tabrizi S, et al. Prevalence of sexually transmitted infections among antenatal women in Vanuatu, 1999-2000. Sex Transm Dis **2003**; 30:362–366.

43. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ **1987**; 65:477–83.

**Tables**

**Table 1.** Grading schemes used in field and photographic grading in this study.

|  |  |  |
| --- | --- | --- |
| **Feature** | **Degree of involvement** | **Grade** |
| Pannus  (measured vertically from the upper limbus) | <2.0 mm extension | 0 |
| 2.0 to <4.0 mm extension | 1 |
| 4.0 to <6.0 mm extension | 2 |
| ≥6.0 mm extension | 3 |
| Herbert’s pits | None | 0 |
| One to three | 1 |
| More than three, but not involving the entire upper lunular | 2 |
| Entire upper lunular involved | 3 |
| Cornea encircled or two rows of pits above | 4 |
| Cicatricae | None | 0 |
| Fine scattered scars on the upper tarsal conjunctiva, or scars on other parts of the conjunctiva (mild) | 1 |
| More severe scarring but without shortening or distortion of the upper tarsus (moderate) | 2 |
| Scarring with distortion of the upper tarsus (severe) | 3 |
| Conjunctival inflammation | Five or more follicles each ≥0.5mm diameter in the central part of the upper tarsal conjunctiva | TF |
| Pronounced inflammatory thickening of the upper tarsal conjunctiva that obscures more than half of the normal deep tarsal vessels | TI |
| Grading systems taken directly from [30,43]and modified from [31].  TF: trachomatous inflammation—follicular; TI: trachomatous inflammation—intense. | | |

**Table 2.** Study population demographics during survey of upper pole corneal pannus, Herbert’s pits and conjunctival scarring in selected villages of the Solomon Islands and Vanuatu, 2018.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Solomon Islands** | **Vanuatu** | **Total** |
| Survey month | June–July 2018 | August 2018 | June–August 2018 |
| Villages visited / villages targeted | 15/16 | 9/11 | 24/27 |
| Households enrolled | 217 | 133 | 350 |
| Household residents aged ≥1 year | 1128 | 835 | 1963 |
| Household residents aged 10–14 years | 332 | 197 | 529 |
| Residents surveyed aged 10–14 years | 323 (97%) | 169 (86%) | 492 (93%) |
| Male 10–14-year-olds surveyed (%) | 51 | 53 | 52 |
| Median (range) 10–14-year-olds  per village | 21 (8–37) | 15 (7–42) | 18 (7–42) |
| Median (range) individuals  per one-year age band | 66 (52–73) | 33 (25–48) | 99 (80–121) |

**Table 3.** Upper pole corneal pannus and Herbert’s pits in children aged 10–14 years in selected villages of the Solomon Islands (n=323) and Vanuatu (n=169), 2018.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | **Solomon Islands**  **(%)** | **Vanuatu**  **(%)** | **Total**  **(%)** |
| **Pannus** | **0** | 283 (88) | 148 (88) | 431 (88) |
| **1** | 40 (12) | 21 (12) | 61 (12) |
| **2** | 0 (0) | 0 (0) | 0 (0) |
| **3** | 0 (0) | 0 (0) | 0 (0) |
| **Herbert’s pits** | **0** | 281 (87) | 160 (95) | 441 (90) |
| **1** | 36 (11) | 9 (5) | 4 (9) |
| **2** | 5 (2) | 0 (0) | 5 (1) |
| **3** | 1 (0.3) | 0 (0) | 1 (0.2) |
| **4** | 0 (0) | 0 (0) | 0 (0) |
| **Scarring** | **C0** | 211 (65) | 151 (89) | 362 (74) |
| **C1** | 86 (27) | 16 (9) | 102 (21) |
| **C2/C3** | 26 (8) | 2 (1) | 28 (6) |
| **TF** | | 83 (26) | 8 (5) | 91 (18) |
| **TI** |  | 4 (1) | 0 (0) | 4 (1) |

**Table 4.** Concurrence of upper pole corneal pannus, Herbert’s pits and conjunctival scars at the individual level in children aged 10–14 years, in selected villages of the Solomon Islands (n=323) and Vanuatu (n=169), 2018. Study outcomes are shown in **bold** font.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Conjunctival scar grade (most severely affected eye)** | | **Herbert’s pits (HPs) and/or pannus (most severely affected eye)** | | | |
| **No (%)** | **Yes (%)** | **Primary outcome (%)\*** | |
| Solomon Islands | C0 | 175 (54) | 36 (11) |  |  |
| C1 | 68 (21) | 18 (6) | **26 (8.0)** |
| C2 | 15 (5) | 5 (2) | **8 (2.5)** |
| C3 | 3 (1) | 3 (1) |
| Vanuatu | C0 | 135 (80) | 16 (9) |  |  |
| C1 | 8 (5) | 8 (5) | **9 (5.3)** |
| C2 | 0 (0) | 0 (0) | **1 (0.6)** |
| C3 | 1 (1) | 1 (1) |
| \* The primary outcomes of the study were the prevalence of defined combinations of signs in 10–14-year-olds, specifically (i) limbal signs (pannus, HPs or both) in at least one eye plus conjunctival scarring (C≥1) in at least one eye; and (ii) limbal signs (pannus, HPs or both) in at least one eye and moderate-to-severe conjunctival scarring (C≥2) in at least one eye. | | | | | |

**Table 5.** Agreement between field and photograph grading.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Grade** | **Comparison** | **Field -Photo -** | **Field -Photo +** | **Field + Photo -** | **Field +**  **Photo +** | **Percent agreement** | **Kappa score** |
| Any scar (C≥1) | Field vs PG1  (n=60) | 32 | 14 | 6 | 8 | 67 | 0.22 |
| Field vs PG2  (n=58) | 43 | 1 | 9 | 5 | 83 | 0.42 |
| Field vs PG consensus  (n=53) | 39 | 2 | 8 | 4 | 81 | 0.69 |
| Any limbal feature  (pannus ≥ 2mm and/or Herbert’s pits) | Field vs PG1  (n=59) | 42 | 8 | 4 | 5 | 80 | 0.34 |
| Field vs PG2  (n=60) | 34 | 17 | 6 | 3 | 62 | 0.00 |
| Field vs PG consensus  (n=57) | 44 | 5 | 1 | 7 | 90 | 0.35 |
| PG: photograder | | | | | | | |

**Figure legends**

**Figure 1.** Age- and gender-adjusted cluster-level TF prevalence in 1–9-year-olds from pre-MDA programmatic mapping data in the (**A**) Solomon Islands [27] and (**B**) Vanuatu [28].

**Figure 2.** Geographical distribution of upper pole corneal pannus, Herbert’s pits and conjunctival scarring by village in (**A**) Western province, Solomon Islands, (**B**) Temotu province, Solomon Islands and (**C**) Vanuatu. Surevys conducted in 2018. The area of each pie chart is proportional to the number of children examined in that village. The legend category is determined at the individual level.

**Figure 3.** Age-sepcific anti-Pgp3 seroprevalence in children aged 10–14 years in selected villages of (**A**) Solomon Islands (n=323) and (**B**) Vanuatu (n=169), 2018. Whiskers represent Wald’s interval around the seroporevalence estimate at the 95% confidence level.

**Supplementary Table 1.** Univariable and multivarible mixed-effects logistic regression of the relationship between having upper pole corneal pannus and/or Herbert’s pits in either eye (i.e., any limbal sign) and age, gender, anti-Pgp3 serostatus, presence of TF and presence of conjunctival scars in children aged 10–14 years (n=492), in selected villages of the Solomon Islands and Vanuatu, 2018. Confidence intervals around odds ratios are calculated using Wald’s test. *P*-values suggesting strong evidence (*p*<0.05), calculated by likelihood ratio testing of models with and without each independent variable, are indicated in **bold**.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | | **Univariable analysis** | | **Multivariable analysis** | |
| **OR**  **(95% CI)** | **p-value** | **aOR**  **(95% CI)** | **p-value** |
| Age (years) | 10–12 | - | - | Not tested | |
| 13–14 | 0.86  (0.51–1.47) | 0.593 |
| Gender | Male | - | - | - | **-** |
| Female | 0.50  (0.30–0.83) | 0.008 | **0.48**  **(0.28–0.82)** | **0.007** |
| TF in either eye | No | - | - | - | **-** |
| Yes | 3.42  (1.86–6.31) | <0.001 | **4.30**  **(2.25–8.22)** | **<0.001** |
| Any scar (C≥1 in either eye) | No | - | - | - | - |
| Yes | 1.85  (1.06–3.23) | 0.034 | **2.30**  **(1.28–4.14)** | **0.006** |
| Country | Solomon Islands | - | - | Not tested | |
| Vanuatu | 0.62  (0.20–1.89) | 0.394 |
| Anti-Pgp3 seropositivity | No | - | - | Not tested | |
| Yes | 1.06  (0.54–2.10) | 0.858 |
| aOR: adjusted odds ratio; C: conjunctival scar graded according to [30]; CI: confidence interval; OR: odds ratio; TF: trachomatous inflammation—follicular. | | | | | |